Metsera soars on Pfizer's $4.9 billion buyout deal

** Shares of obesity drug developer Metsera MTSR.O jump 56.3% to $52.08 premarket

** Pfizer PFE.N says it will buy Metsera in a deal valued at $4.9 billion

** PFE will pay MTSR for $47.50 per share in cash, with an additional $22.50 per share contingent on the achievement of certain performance milestones

** The $47.50 per share deal represents a 42.6% premium over MTSR's Friday closing price of $33.32

** The deal is expected to close in fourth quarter of 2025

** PFE shares up 2.8% premarket

** Up to last close, MTSR stock up ~85%, PFE down 9% YTD